CEL-SCI widens licensing deal with Teva

As per the original agreement, Teva is responsible for marketing and distributing Multikine in Israel and Turkey, while the extended agreement allows Teva to include Croatia and Serbia.

Now, Teva has the responsibility to bear the costs of registering and selling the product in Serbia and Croatia.

The extended deal enables CEL-SCI to get milestone payments from Teva.

CEL-SCI’s Phase III clinical trial of Multikine is an open-label, randomized, controlled, multi-center study which aims to establish Multikine as a first-line standard of care therapy in treating newly diagnosed head and neck cancer patients.

CEL-SCI CEO Geert Kersten said strengthening this relationship will help in maximizing Multikine’s potential in developing markets while retaining rights to market Multikine in North America and most of Europe.